|
Overall survival in newly diagnosed MM patients with del(17p): A report from the Connect MM Registry. |
| |
|
Consulting or Advisory Role - Celgene; Millennium; Novartis; Onyx |
Research Funding - Array BioPharma; Celgene; Millennium; Novartis; Onyx |
| |
|
Honoraria - Celgene; Onyx; Takeda |
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene; Onyx; Takeda |
Travel, Accommodations, Expenses - Celgene; Onyx; Takeda |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Millennium |
| |
|
Speakers' Bureau - Amgen; Celgene; Millennium; Pharmacyclics |
| |
|
Consulting or Advisory Role - Celgene; Millennium; Onyx |
Speakers' Bureau - Millennium |
Research Funding - Celgene |
| |
|
Consulting or Advisory Role - Celgene |
| |
|
Research Funding - Celgene |
| |
|
|
Stock and Other Ownership Interests - Celgene |
| |
|
|
Stock and Other Ownership Interests - Celgene |
| |
|
|
Stock and Other Ownership Interests - Celgene |
| |
|
|
| |
|
Consulting or Advisory Role - Amgen; Celgene; Millennium; Onyx; Takeda |